As an inhibitor of NPC1L1 [6], ezetimibe (EZE) can effectively lower the plasma LDL-cholesterol [7] and decrease the risk of CGD, as shown in the previous study [8]. The gene discussed is NPC1L1; the disease is chronic granulomatous disease.